Valproate MHRA Guidance: Limitations and Opportunities

Valproate MHRA Guidance: Limitations and Opportunities

Recent publication of the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has strengthened the regulatory measures for valproate medicines. It highlights the importance of making women of childbearing age with epilepsy aware of the teratogenic risks of valproate and...

Full description

Bibliographic Details
Main Authors: Lance Watkins, Hannah Cock, Heather Angus-Leppan, Kim Morley, Mike Wilcock, Rohit Shankar
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Neurology
Subjects:
valproate
pregnancy
communication
risk assessment
intellectual disability
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2019.00139/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2019.00139/full

Similar Items